Jonathan Nash congratulates Affect Therapeutics, on their successful $26 million Series B funding
“LifeArc Ventures is pleased to participate in Affect Therapeutics’ $26 million Series B financing alongside Allumia Ventures, Artis Ventures, City Light Capital, and Limitless Ventures. Accessible via smartphone, Affect’s virtual clinic brings together contingency management, structured counselling, medication management, and peer support, all supported by an AI-driven clinical decision-support system that delivers real-time triage, crisis response, and personalised care. The company currently operates in 20 US states and offers coverage through Medicaid, Medicare, and employer/commercial plans. This investment will help the company expand its footprint and deepen partnerships with payers and health systems, bringing evidence-based care to many more people.”
